JP2014513069A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513069A5
JP2014513069A5 JP2014502905A JP2014502905A JP2014513069A5 JP 2014513069 A5 JP2014513069 A5 JP 2014513069A5 JP 2014502905 A JP2014502905 A JP 2014502905A JP 2014502905 A JP2014502905 A JP 2014502905A JP 2014513069 A5 JP2014513069 A5 JP 2014513069A5
Authority
JP
Japan
Prior art keywords
cell
dna
dosage unit
antibody
pharmaceutical dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014502905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513069A (ja
JP6178785B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/031860 external-priority patent/WO2012135831A1/en
Publication of JP2014513069A publication Critical patent/JP2014513069A/ja
Publication of JP2014513069A5 publication Critical patent/JP2014513069A5/ja
Application granted granted Critical
Publication of JP6178785B2 publication Critical patent/JP6178785B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014502905A 2011-04-01 2012-04-02 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用 Active JP6178785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161470918P 2011-04-01 2011-04-01
US61/470,918 2011-04-01
PCT/US2012/031860 WO2012135831A1 (en) 2011-04-01 2012-04-02 Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016025916A Division JP2016094479A (ja) 2011-04-01 2016-02-15 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用

Publications (3)

Publication Number Publication Date
JP2014513069A JP2014513069A (ja) 2014-05-29
JP2014513069A5 true JP2014513069A5 (cg-RX-API-DMAC7.html) 2015-03-05
JP6178785B2 JP6178785B2 (ja) 2017-08-09

Family

ID=46147672

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014502905A Active JP6178785B2 (ja) 2011-04-01 2012-04-02 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用
JP2016025916A Withdrawn JP2016094479A (ja) 2011-04-01 2016-02-15 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016025916A Withdrawn JP2016094479A (ja) 2011-04-01 2016-02-15 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用

Country Status (6)

Country Link
US (4) US9701740B2 (cg-RX-API-DMAC7.html)
EP (2) EP3597665A1 (cg-RX-API-DMAC7.html)
JP (2) JP6178785B2 (cg-RX-API-DMAC7.html)
CN (1) CN103874710B (cg-RX-API-DMAC7.html)
ES (1) ES2744840T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012135831A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6178785B2 (ja) 2011-04-01 2017-08-09 イェール ユニバーシティーYale University 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用
US9732146B2 (en) 2012-03-30 2017-08-15 The United States Of America As Represented By The Department Of Veterans Affairs Antibody-mediated transduction of heat shock proteins into living cells
US12195550B2 (en) 2012-03-30 2025-01-14 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
EP2968371A4 (en) * 2013-03-12 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
KR102522346B1 (ko) * 2013-08-29 2023-04-17 시티 오브 호프 세포침투 콘주게이트 및 이의 사용 방법
EP3073825A4 (en) * 2013-11-25 2017-06-21 The University of Toledo Inhibitors of ercc1-xpf and methods of using the same
WO2015106290A1 (en) * 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
WO2015134607A1 (en) 2014-03-04 2015-09-11 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
KR101602876B1 (ko) 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR101602870B1 (ko) * 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
CA2995673A1 (en) * 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
JP2017534571A (ja) * 2014-08-28 2017-11-24 イェール ユニバーシティーYale University 抗体3e10の多価フラグメントおよびその使用方法
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
JP2019520086A (ja) 2016-05-27 2019-07-18 オラム・セラピューティクス・インコーポレイテッド 細胞質浸透抗体およびその用途
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
US11613590B2 (en) * 2017-07-17 2023-03-28 Nucleus Therapeutics Pty. Ltd Binding proteins 1
US11129894B2 (en) * 2017-09-29 2021-09-28 - Humanetics Corporation Sensitizing cells to proton radiation
EP3502700A1 (en) * 2017-12-21 2019-06-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods based on the detection of rad51 foci in tumor cells
US12304970B2 (en) 2018-02-01 2025-05-20 Yale University Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus
US20210137960A1 (en) 2018-02-01 2021-05-13 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
KR20190143826A (ko) 2018-06-21 2019-12-31 오름테라퓨틱 주식회사 세포/조직 특이적 세포 침투 항체
EP3844287B1 (en) 2018-08-31 2024-05-22 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
WO2021015986A1 (en) * 2019-07-19 2021-01-28 Dana-Farber Cancer Institute, Inc. Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
KR20220101073A (ko) 2019-08-30 2022-07-19 예일 유니버시티 핵산을 세포로 전달하기 위한 조성물 및 방법
WO2021077070A1 (en) 2019-10-18 2021-04-22 Yale University Compositions and methods for inhibition of cell-penetrating antibodies
CN116171152A (zh) * 2020-09-15 2023-05-26 昂科因凡特公司 制备的镭-224和子代联合dna修复抑制剂,用于放射性核素治疗
EP4396225A4 (en) * 2021-08-30 2025-07-02 Nucleus Therapeutics Pty Ltd METHOD OF TREATMENT
CN115998885B (zh) * 2021-10-22 2024-11-12 上海科技大学 抑制剂组合及其在制备治疗myc高表达癌症的药物中的应用
CN116120398B (zh) * 2023-02-23 2024-08-23 南开大学 多肽kwqrksirh、制备方法及其在增敏致dna损伤类肿瘤疗法中的应用
WO2025111420A1 (en) * 2023-11-21 2025-05-30 Oklahoma Medical Research Foundation Fully human dna binding monoclonal antibodies

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812397A (en) 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
US20030109475A1 (en) 1991-12-17 2003-06-12 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
ES2150573T3 (es) * 1994-06-24 2000-12-01 Vladimir P Torchilin Composicion que contiene autoanticuerpos para la terapia y profilaxis tumorales.
WO1997032602A1 (en) 1996-03-08 1997-09-12 The Regents Of The University Of California DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF
AU2001257001A1 (en) 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
WO2004033705A2 (en) 2001-10-10 2004-04-22 Mount Sinai School Of Medicine Of The City University Of New York Viral interferon antagonists and uses therefor
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
GB0229251D0 (en) 2002-12-13 2003-01-22 Koninkl Philips Electronics Nv Internet and tv data service browsing apparatus
WO2004066961A2 (en) 2003-01-20 2004-08-12 St. Jude Children's Research Hospital Use of sendai virus as a human parainfluenza vaccine
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
RU2269356C2 (ru) * 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
EP1666055A4 (en) 2003-07-14 2010-02-10 Viktor Veniaminovich Tets METHOD OF TREATMENT OF ONCOLOGICAL, INFECTIOUS, AND SOMATIC DISEASES, METHODS OF MONITORING THE EFFICACY OF TREATMENT, AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF
JP2007526253A (ja) 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ,インコーポレイテッド 免疫刺激性ウイルスrnaオリゴヌクレオチド
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
EP1968643A2 (en) 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
FR2899902B1 (fr) 2006-04-18 2012-01-27 Agronomique Inst Nat Rech Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet et leurs utilisations pour la vaccination et la vectorisation intra-cellulaire.
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
GB0615662D0 (en) 2006-08-07 2006-09-13 Affitech As Antibody
AU2008207948A1 (en) 2007-01-22 2008-07-31 The United States Government As Represented By The Department Of Veterans Affairs Use of antibody conjugates
JP4936482B2 (ja) 2007-04-13 2012-05-23 独立行政法人産業技術総合研究所 改良された持続感染型センダイウイルスベクター
JP2010527618A (ja) * 2007-05-24 2010-08-19 アメリカ合衆国 ヌクレオシドサルベージ経路を通しての核内タンパク質伝達
CA2692072A1 (en) * 2007-06-13 2008-12-24 Massachusetts Institute Of Technology Methods and agents for inhibiting tumor growth
EP2200652B1 (en) 2007-09-27 2018-03-21 Children's Medical Center Corporation Microbubbles and methods for oxygen delivery
EP2279002B1 (en) * 2008-04-30 2013-08-14 Ajou University Industry-Academic Cooperation Foundation Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
CN102037058B (zh) 2008-05-23 2013-08-07 那野伽利阿株式会社 多西紫杉醇高分子衍生物、及其制造方法及其用途
CN101808668B (zh) 2008-07-29 2012-06-27 那野伽利阿株式会社 药物内包活性靶向型高分子微团、医药组合物
CA2777486A1 (en) 2008-10-15 2010-04-22 4S3 Bioscience Inc. Methods and compositions for treatment of myotonic dystrophy
CN102209726A (zh) 2008-11-11 2011-10-05 亚州大学校产学协力团 具有细胞穿透性、序列特异性和核酸水解性的抗体、其制备方法及包含所述抗体的药物组合物
US9155801B2 (en) 2009-05-28 2015-10-13 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
US9365866B2 (en) 2009-06-03 2016-06-14 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
US8496941B2 (en) 2009-06-03 2013-07-30 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
AU2010260145B2 (en) 2009-06-15 2015-08-20 Valerion Therapeutics, Llc Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides
EP2477550A4 (en) 2009-09-15 2013-12-04 Univ Columbia SYSTEMS, METHODS AND DEVICES FOR MICROBUBBLES
WO2012145125A1 (en) 2011-03-25 2012-10-26 4S3 Bioscience Inc. Targeted radionuclides
JP6178785B2 (ja) 2011-04-01 2017-08-09 イェール ユニバーシティーYale University 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用
JP5921119B2 (ja) 2011-09-02 2016-05-24 株式会社東芝 X線診断装置
WO2013096835A1 (en) 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
US9732146B2 (en) 2012-03-30 2017-08-15 The United States Of America As Represented By The Department Of Veterans Affairs Antibody-mediated transduction of heat shock proteins into living cells
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
US20150152170A1 (en) 2012-05-23 2015-06-04 Valerion Therapeutics, Llc Methods for increasing muscle contractility
EP3415525B1 (en) 2012-12-07 2022-01-05 Phion Therapeutics Limited An amphipathic peptide
WO2014130722A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of forbes-cori disease
JP2016514096A (ja) 2013-02-20 2016-05-19 バレリオン セラピューティクス, エルエルシー ポンぺ病の処置のための方法および組成物
US20160114058A1 (en) 2013-05-17 2016-04-28 Nanocarrier Co., Ltd. Polymer micelle pharmaceutical composition
WO2015106290A1 (en) 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
WO2015134607A1 (en) 2014-03-04 2015-09-11 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations
EP3154570A4 (en) 2014-06-13 2017-12-27 Valerion Therapeutics, LLC Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
WO2016013870A1 (ko) 2014-07-22 2016-01-28 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
JP2017534571A (ja) 2014-08-28 2017-11-24 イェール ユニバーシティーYale University 抗体3e10の多価フラグメントおよびその使用方法
WO2016054509A1 (en) 2014-10-02 2016-04-07 Q-State Biosciences, Inc. Systems and methods for assessing inter-cell communication
US10383945B2 (en) 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
CA3036524A1 (en) 2016-09-09 2018-03-15 Valerion Therapeutics, Llc Methods and compositions for treatment of lafora disease
US11613590B2 (en) 2017-07-17 2023-03-28 Nucleus Therapeutics Pty. Ltd Binding proteins 1
JP2021518840A (ja) 2018-03-15 2021-08-05 バレリオン セラピューティクス, エルエルシー ポリグルコサン障害の処置のための方法及び組成物
BR112021003823A2 (pt) 2018-08-31 2021-05-25 Yale University composição, composição farmacêutica e método para modificar o genoma de uma célula
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
EP3844287B1 (en) 2018-08-31 2024-05-22 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing

Similar Documents

Publication Publication Date Title
JP2017534571A5 (cg-RX-API-DMAC7.html)
Riches et al. Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically
Zhang et al. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy
Ooki et al. Immunotherapy in colorectal cancer: current and future strategies
US20240247056A1 (en) Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair
US11564927B2 (en) Therapeutic compositions, combinations, and methods of use
Liu et al. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
JP2020527332A5 (cg-RX-API-DMAC7.html)
JP2018501254A5 (cg-RX-API-DMAC7.html)
Milenic et al. Targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease: An investigation of the human anti-EGFR monoclonal antibody, panitumumab
Tran et al. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1
Liu et al. RET kinase alterations in targeted cancer therapy
TW202302087A (zh) 使用mdm2拮抗劑的癌症療法之生物標記
JP2023546679A (ja) がん治療における放射免疫療法とcd47遮断の併用
Rahnama et al. Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality
Wang et al. A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer
CN114616246B (zh) 卷曲受体抗体及其用途
HK40121585A (en) Therapeutic compositions, combinations, and methods of use
EP4561612A1 (en) Anti-garp-tgf-beta1/pd-1 combination therapy
HK40021615A (en) Cell-penetrating anti-dna antibodies and uses thereof to inhibit dna repair
Baker et al. Anti-angiogenic activity of Motamine using the quantitative in vivo Matrigel chamber angiogenesis assay
HK1254525B (en) Therapeutic compositions, combinations, and methods of use